Biomarin Pharmaceutical Inc
XBER:BM8
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43.8
68.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BM8
stock under the Base Case scenario is
66.32
EUR.
Compared to the current market price of 50.06 EUR,
Biomarin Pharmaceutical Inc
is
Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Biomarin Pharmaceutical Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Recent regulatory hurdles for BioMarin’s gene therapy portfolio, including potential FDA delays for innovative treatments like valoctocogene roxaparvovec for hemophilia A, could significantly slow revenue growth and erode investor confidence.
The high cost and narrow patient base of BioMarin’s enzyme replacement therapies, such as Vimizim and Naglazyme, expose the company to reimbursement pressures, which could be exacerbated by payers pushing back on premium pricing in rare disease markets.
Failure to diversify beyond a few core rare disease franchises increases BioMarin’s vulnerability to competitive threats and patent cliffs, potentially leading to revenue stagnation if pipeline programs fall short of expectations.
BioMarin’s deep pipeline in rare genetic disorders, including multiple late-stage gene therapy candidates, positions the company as a leader in high-value, underserved orphan markets, with strong prospects for breakthrough designations.
The firm’s proven track record with commercialized products like Vimizim and Palynziq underlines its expertise in navigating complex regulatory pathways for rare diseases, offering a competitive moat in the orphan drug space.
Management’s focus on in-house manufacturing capabilities for gene therapies provides strategic control over the production process, potentially enabling quicker scale-up and higher margins once therapies gain approval.
Revenue & Expenses Breakdown
Biomarin Pharmaceutical Inc
Balance Sheet Decomposition
Biomarin Pharmaceutical Inc
| Current Assets | 3.9B |
| Cash & Short-Term Investments | 1.5B |
| Receivables | 790.3m |
| Other Current Assets | 1.6B |
| Non-Current Assets | 3.8B |
| Long-Term Investments | 512.9m |
| PP&E | 1B |
| Intangibles | 429.3m |
| Other Non-Current Assets | 1.8B |
| Current Liabilities | 798.4m |
| Accounts Payable | 389.7m |
| Accrued Liabilities | 354.9m |
| Other Current Liabilities | 53.8m |
| Non-Current Liabilities | 759.7m |
| Long-Term Debt | 596.7m |
| Other Non-Current Liabilities | 163.1m |
Free Cash Flow Analysis
Biomarin Pharmaceutical Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Biomarin Pharmaceutical Inc
|
Revenue
|
3.1B
USD
|
|
Cost of Revenue
|
-577.9m
USD
|
|
Gross Profit
|
2.5B
USD
|
|
Operating Expenses
|
-1.9B
USD
|
|
Operating Income
|
625.3m
USD
|
|
Other Expenses
|
-104.9m
USD
|
|
Net Income
|
520.4m
USD
|
BM8 Profitability Score
Profitability Due Diligence
Biomarin Pharmaceutical Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Biomarin Pharmaceutical Inc's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
BM8 Solvency Score
Solvency Due Diligence
Biomarin Pharmaceutical Inc's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Score
Biomarin Pharmaceutical Inc's solvency score is 96/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BM8 Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for
BM8
is 80.14 EUR
with a low forecast of 47.88 EUR and a high forecast of 110.42 EUR.
Dividends
Current shareholder yield for
BMRN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BM8
stock under the Base Case scenario is
66.32
EUR.
Compared to the current market price of 50.06 EUR,
Biomarin Pharmaceutical Inc
is
Undervalued by 25%.